Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Neal Bhatia

Dermatology San Diego, CA Medical Doctor

NPI 1255349288 CMS profile 11650

9025 Balboa Avenue, Suite 105, San Diego, CA 92123

Open in the dashboard

General payments

$2,486,105

3,272 records reported · program years 2019–2025

Research payments

$42,797

Paid to them · 21 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,572,364 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Neal Bhatia of San Diego, CA is reported in the CMS Open Payments database as having received $2,486,105 across 3,272 general payments and $42,797 in research payments paid to them. Separately, studies naming them as principal investigator received $2,572,364 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $352,597 543
2024 General $440,505 562
2024 Research $105 1
2023 General $421,820 618
2022 General $588,421 657
2022 Research $3,200 1
2021 General $342,435 404
2021 Research $5,332 4
2020 General $159,898 205
2020 Research $2,300 5
2019 General $180,429 283
2019 Research $31,861 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neal Bhatia
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Neal Bhatia were reported at $352,597. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Neal Bhatia Dermatology median Middle half National median
2019 $180,429 $454 $129–$1,240 $163
2020 $159,898 $235 $81–$756 $114
2021 $342,435 $377 $108–$1,108 $132
2022 $588,421 $514 $143–$1,391 $149
2023 $421,820 $607 $159–$1,674 $160
2024 $440,505 $751 $204–$1,903 $164
2025 $352,597 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sun Pharmaceutical Industries Inc. $292,700 349 payments
  2. AbbVie, Inc. $250,939 251 payments
  3. Genzyme Corporation $241,923 236 payments
  4. Pfizer Inc. $229,860 173 payments
  5. E.R. Squibb & Sons, L.L.C. $222,994 281 payments
  6. Ortho Dermatologics, a division of Bausch Health US, LLC $187,416 259 payments
  7. Regeneron Healthcare Solutions, Inc. $158,232 187 payments
  8. LEO Pharma Inc. $143,990 183 payments
  9. Almirall LLC $107,988 108 payments
  10. Incyte Corporation $73,965 133 payments
  11. Other $576,097 1,112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,349,289 388 payments
  2. Consulting Fee $630,699 222 payments
  3. Travel and Lodging $169,748 574 payments
  4. Honoraria $101,576 44 payments
  5. Food and Beverage $98,901 1,986 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $62,995 20 payments
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $41,400 18 payments
  8. Education $31,380 19 payments
  9. Gift $117 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $245,762 232 payments
  2. RINVOQ $244,406 221 payments
  3. SOTYKTU $153,981 211 payments
  4. DUPIXENT Inflammation And Immunology $133,703 140 payments
  5. CIBINQO $107,674 92 payments
  6. ADBRY $98,641 132 payments
  7. LEVULAN KERASTICK $94,559 53 payments
  8. OPZELURA $71,014 117 payments
  9. DUOBRII $69,140 94 payments
  10. Winlevi $67,614 96 payments
  11. Other $1,073,198 1,936 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Bausch Health US, LLC $20,352 4 payments
  2. Pfizer Inc. $8,940 6 payments
  3. Mayne Pharma Inc. $6,248 4 payments
  4. Eli Lilly and Company $5,515 4 payments
  5. Amgen Inc. $1,742 3 payments

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$11,179

Medicare's payments for the services billed

Medicare patients

53

Average age 73

Services billed

179

32 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 43%
Arthritis 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
$84,530 — —
RINVOQ
$55,463 — —
Zoryve
$39,223 — —
SPEVIGO
$38,865 — —
CIBINQO
$32,895 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

3,293 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record